RECRUITINGOBSERVATIONAL
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
About This Trial
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as clinicians across primary and tertiary care to study the immune, lipid and metabolic drivers of early cardiovascular disease. RESET incorporates a nested randomised controlled trials (RCT) to test the use of a combined digital wearable and AI-human symbiotic lifestyle intervention to halt or reverse the progression of early disease.
Who May Be Eligible (Plain English)
Who May Qualify:
- 40-70 years old
- ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher
Who Should NOT Join This Trial:
- Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
- Limited life expectancy
- Other ongoing unstable medical conditions
- Pregnant women
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 40-70 years old
* ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher
Exclusion Criteria:
* Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke)
* Limited life expectancy
* Other ongoing unstable medical conditions
* Pregnant women
Treatments Being Tested
BEHAVIORAL
Digital wearable and AI-human symbiotic lifestyle intervention
Digital wearable and AI-human symbiotic lifestyle intervention
Locations (1)
NUS
Singapore, Singapore